has a long half-life allowing for once-daily dosing in treatment-naive patients and has less pharmacokinetic variability compared with other HIV INSTIs. For treatment-naive patients, dolutegravir ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback